By complexing RES with cyclodextrin (CD) and encapsulating it in poly lactic glycolic acid (PLGA) NPs, functionalized with transferrin ligands, the researchers aimed to improve RES targeting to NSCLC cells via transferrin receptor (TfR)-mediated endocytosis, thereby enhancing therapeutic outcomes and reducing off-target toxicity. Here, TF is linked to non-small cell lung carcinoma.